Microbiology

United Methicillin Resistant Staphylococcus Aureus (MRSA) Infections Market and Competitive Landscape Report 2020 - ResearchAndMarkets.com

Friday, September 18, 2020 - 3:50pm

The "US Methicillin Resistant Staphylococcus Aureus Infections Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Methicillin Resistant Staphylococcus Aureus Infections Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • US Methicillin Resistant Staphylococcus Aureus Infections Market and Competitive Landscape Highlights - 2020, provides comprehensive insights into Methicillin Resistant Staphylococcus Aureus Infections pipeline products, Methicillin Resistant Staphylococcus Aureus Infections epidemiology, Methicillin Resistant Staphylococcus Aureus Infections market valuations and forecast, Methicillin Resistant Staphylococcus Aureus Infections drugs sales and competitive landscape in the US.
  • Methicillin Resistant Staphylococcus Aureus Infections pipeline: Find out the products in clinical trials for the treatment of Methicillin Resistant Staphylococcus Aureus Infections by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Methicillin Resistant Staphylococcus Aureus Infections epidemiology: Find out the number of patients diagnosed (prevalence) with Methicillin Resistant Staphylococcus Aureus Infections in the US
    Methicillin Resistant Staphylococcus Aureus Infections drugs: Identify key products marketed and prescribed for Methicillin Resistant Staphylococcus Aureus Infections in the US, including trade name, molecule name, and company
    Methicillin Resistant Staphylococcus Aureus Infections drugs sales: Find out the sales revenues of Methicillin Resistant Staphylococcus Aureus Infections drugs in the US
    Methicillin Resistant Staphylococcus Aureus Infections market valuations: Find out the market size for Methicillin Resistant Staphylococcus Aureus Infections drugs in 2019 in the US.
  • Find out how the market advanced from 2016 and forecast to 2025
    Methicillin Resistant Staphylococcus Aureus Infections drugs market share: Find out the market shares for key Methicillin Resistant Staphylococcus Aureus Infections drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Methicillin Resistant Staphylococcus Aureus Infections products
    View source version on businesswire.com: https://www.businesswire.com/news/home/20200918005395/en/

Electroporation Instruments Market and Competitive Landscape & Pandemic Recovery Analysis 2020 - Technavio

Friday, September 18, 2020 - 12:15am
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20200917005676/en/
    Technavio has announced its latest market research report titled Global Electroporation Instruments Market 2020-2024 (Graphic: Business Wire)
    The research is classified into seven sections electroporation instruments market landscape, market sizing, five force analysis, customer landscape, geographic landscape, drivers, challenges, and trends, and vendor landscape and analysis.
  • Download Free Sample Report on COVID-19 Recovery Analysis
    Electroporation Instruments Vendors: Identify key vendors of the electroporation instruments market, including company-revenue, market presence, influence-index, vendor-classification, and market positioning.
  • Electroporation Instruments Region Growth: Find out the highest and slowest growth of regions for electroporation instruments market.
  • Electroporation Instruments Market Valuations: Find out the global market size for electroporation instruments in 2019 and how the market will advance from 2020 to 2024.

Shoreline Biome Receives Patent for Innovative Bacteria Lysis Method

Wednesday, September 16, 2020 - 2:00pm

The patent outlines the method and materials for the lysis of bacteria present in microbiomes as well as bacterial cell isolates.

Key Points: 
  • The patent outlines the method and materials for the lysis of bacteria present in microbiomes as well as bacterial cell isolates.
  • This method, used in the Shoreline Biome Rapid Prep Kits and in the front end of the Shoreline Complete kits , provides researchers with a set of reagents to quickly, comprehensively, and uniformly lyse bacteria.
  • Shoreline Biome sells the reagents used in this method in 16-well and 96-well plate format.
  • Shoreline Biome accelerates breakthroughs in microbiome research by developing transformative discovery tools that characterize microbiome populations down to the strain level.

Biocodex Microbiota Foundation U.S. Research Grant Supports Ground-Breaking Research on Gut Microbiota, Now Accepting 2020 Applicants

Tuesday, September 15, 2020 - 2:00pm

Biocodex Microbiota Foundation's annual call for grant applications is part of a multi-year research initiative to understand the interaction between microbiota and different pathologies.

Key Points: 
  • Biocodex Microbiota Foundation's annual call for grant applications is part of a multi-year research initiative to understand the interaction between microbiota and different pathologies.
  • To learn more information about Biocodex Microbiota Foundation and the 2020 U.S. grant program click here .
  • The Biocodex Microbiota Foundation's mission is to support research into microbiota and its interaction with various pathologies.
  • The Biocodex Microbiota Foundation supports both foundational and applied research, and projects are selected annually by a committee of independent scientists.

Biosenta Announces Royalty License Agreement for North American Distribution

Monday, September 14, 2020 - 9:58pm

This license will give the rights for distribution of DualXtiv, a broad-spectrum anti-microbial disinfectant, to club level, mass grocery, and retail chains across North America.

Key Points: 
  • This license will give the rights for distribution of DualXtiv, a broad-spectrum anti-microbial disinfectant, to club level, mass grocery, and retail chains across North America.
  • Am Gill, President and CEO, indicating, "This partnership allows for Biosenta's patented formulation to be licensed and sold at scale across North America.
  • Biosenta Inc. develops and manufactures a range of wet and dry chemical compounds for household and industrial applications using advanced encapsulated nanotechnology.
  • Biosenta disinfectants and cleaners kill 99.9% of mold, fungi, bacteria and viruses on contact and prevent re-growth.

Moskitofree Launches Aeriashield

Monday, September 14, 2020 - 5:17pm

The service of Doctor Michle Vialette, Head of Service of the Microbiological Safety Unit, responsible for the High Safety Laboratory at the Pasteur Institute in Lille, supervised the tests on the Aeriashield devices.

Key Points: 
  • The service of Doctor Michle Vialette, Head of Service of the Microbiological Safety Unit, responsible for the High Safety Laboratory at the Pasteur Institute in Lille, supervised the tests on the Aeriashield devices.
  • The Aeriashield by Moskitofree device, tested by the Institut Pasteur De Lille, eliminates 99% of the human coronavirus HCoV-229E within 5 minutes in the air of a sealed enclosure (1.4 m3).
  • Aeriashield by Moskitofree is available in 2 models: individual (portable device) and collective (device to be placed on a table).
  • Aeriashield by Moskitofree provides an eective complementary response to fight against airborne contamination.

Armata Pharmaceuticals Announces Participation in Upcoming Investor Conferences

Friday, September 11, 2020 - 12:30pm

MARINA DEL REY, Calif., Sept. 11, 2020 /PRNewswire/ --Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that management will be participating in two upcoming investor conferences.

Key Points: 
  • MARINA DEL REY, Calif., Sept. 11, 2020 /PRNewswire/ --Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that management will be participating in two upcoming investor conferences.
  • Armata is a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology.
  • Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens.
  • Armata is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.

Seres Therapeutics Announces U.S. Food and Drug Administration Correspondence Following Positive SER-109 Phase 3 Study Results

Friday, September 11, 2020 - 12:00pm

After obtaining highly statistically significant topline Phase 3 ECOSPOR III SER-109 study results in recurrent CDI, Seres requested a Breakthrough Therapy Designation meeting with the FDA.

Key Points: 
  • After obtaining highly statistically significant topline Phase 3 ECOSPOR III SER-109 study results in recurrent CDI, Seres requested a Breakthrough Therapy Designation meeting with the FDA.
  • Seres is taking various measures to expedite open-label study enrollment, including increasing the number of SER-109 clinical study sites across the U.S. and Canada.
  • Seres also anticipates that the quarantine of material used for unapproved Fecal Microbiota Transplantation (FMT) by a national provider will accelerate SER-109 open-label study enrollment.
  • Seres SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA.

COVID-19 Impact & Recovery Analysis - Penicillin Market 2020-2024 | Comorbidities Associated with Bacterial Infections to Boost Growth | Technavio

Thursday, September 10, 2020 - 1:15am

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR40093

Key Points: 
  • To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR40093
    Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources.
  • Our penicillin market report covers the following areas:
    This study identifies the rising awareness about infectious diseases as one of the prime reasons driving the penicillin market growth during the next few years.
  • Backed with competitive intelligence and benchmarking, our research reports on the Penicillin Market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.
  • Register for a free trial today and gain instant access to 17,000+ market research reports.

Prominent Australian and Russian Research Institutions Join Global Virus Network to Combat Viral Diseases

Wednesday, September 9, 2020 - 2:42pm

The two new institutions bring GVN's total number of Centers of Excellence to 57, along with 10 affiliates in 33 countries.

Key Points: 
  • The two new institutions bring GVN's total number of Centers of Excellence to 57, along with 10 affiliates in 33 countries.
  • "EVIT will strengthen our depth and collaborative network in arbovirology, particularly in the Asia-Pacific region, Southeast Asia, India, South America and South Africa.
  • The Chumakov Center has unique expertise in varying areas of virology with many global connections, making it Russia's leading research organization in the field of virology."
  • Additionally, EVIT focuses on emerging viruses such as Hendra and SARS-CoV-2, and established viruses such as influenza virus and respiratory syncytial virus.